Sanofi Confident Of Strategy As China Becomes No.3 Market
This article was originally published in PharmAsia News
Executive Summary
Generic competition to Plavix in Japan was one factor that contributed to China becoming Sanofi's third largest market globally after the US and Western EU by the end of last year, and the French group says it expects to continue to grow ahead of the Chinese market.